Grigorios Xepapadakis

666 total citations
24 papers, 333 citations indexed

About

Grigorios Xepapadakis is a scholar working on Genetics, Cancer Research and Oncology. According to data from OpenAlex, Grigorios Xepapadakis has authored 24 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 12 papers in Cancer Research and 10 papers in Oncology. Recurrent topics in Grigorios Xepapadakis's work include Estrogen and related hormone effects (11 papers), Breast Cancer Treatment Studies (6 papers) and Cancer, Lipids, and Metabolism (5 papers). Grigorios Xepapadakis is often cited by papers focused on Estrogen and related hormone effects (11 papers), Breast Cancer Treatment Studies (6 papers) and Cancer, Lipids, and Metabolism (5 papers). Grigorios Xepapadakis collaborates with scholars based in Greece, United States and Denmark. Grigorios Xepapadakis's co-authors include Christos Markopoulos, Helen Gogas, J. Papadiamantis, Urania Dafni, Z. Antonopoulou, Dimitrios Ntountaniotis, Dimitrios Koukouras, Christina Kostara, Maria Skouroliakou and Gerasimos Siasos and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Grigorios Xepapadakis

23 papers receiving 328 citations

Peers

Grigorios Xepapadakis
Judy-Anne W. Chapman Canada
Andrea De Censi Italy
S. Ashley United Kingdom
Messan G. Amewou-Atisso United States
Henrik Csaba Horváth Hungary
S.E. Bulun United States
T. Vandorpe Belgium
Rosalind Wilson Australia
C. A. Haiman United States
Angeline A. Giangreco United States
Judy-Anne W. Chapman Canada
Grigorios Xepapadakis
Citations per year, relative to Grigorios Xepapadakis Grigorios Xepapadakis (= 1×) peers Judy-Anne W. Chapman

Countries citing papers authored by Grigorios Xepapadakis

Since Specialization
Citations

This map shows the geographic impact of Grigorios Xepapadakis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grigorios Xepapadakis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grigorios Xepapadakis more than expected).

Fields of papers citing papers by Grigorios Xepapadakis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grigorios Xepapadakis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grigorios Xepapadakis. The network helps show where Grigorios Xepapadakis may publish in the future.

Co-authorship network of co-authors of Grigorios Xepapadakis

This figure shows the co-authorship network connecting the top 25 collaborators of Grigorios Xepapadakis. A scholar is included among the top collaborators of Grigorios Xepapadakis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grigorios Xepapadakis. Grigorios Xepapadakis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Apessos, Angela, Κωνσταντίνος Αγιαννιτόπουλος, Georgios Tsaousis, et al.. (2017). Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center. Cancer Genetics. 220. 1–12. 9 indexed citations
2.
Skouroliakou, Maria, et al.. (2017). Serum antioxidant capacity, biochemical profile and body composition of breast cancer survivors in a randomized Mediterranean dietary intervention study. European Journal of Nutrition. 57(6). 2133–2145. 49 indexed citations
3.
4.
Kotoula, Vassiliki, Mattheos Bobos, Zoi Alexopoulou, et al.. (2014). Adjusting Breast Cancer Patient Prognosis with Non-HER2-Gene Patterns on Chromosome 17. PLoS ONE. 9(8). e103707–e103707. 4 indexed citations
5.
Lagoudianakis, Emmanuel, et al.. (2014). Single centre clinical study of a Greek patient population with triple-negative breast cancer. Hellenic Journal of Surgery. 86(5). 280–286.
6.
Xepapadakis, Grigorios, et al.. (2014). Prognostic value of EZH2, paxillin expression and DNA ploidy of breast adenocarcinoma: correlation to pathologic predictors.. PubMed. 18(4). 879–85. 6 indexed citations
7.
Markopoulos, Christos, et al.. (2012). Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. Journal of Cancer Research and Clinical Oncology. 138(9). 1569–1577. 5 indexed citations
8.
Patsouris, E, Emmanuel Lagoudianakis, Athanasios Pappas, et al.. (2011). The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors.. PubMed. 32(2). 156–9. 14 indexed citations
9.
Markopoulos, Christos, et al.. (2011). 5165 POSTER Clinical Use of OncotypeDX Recurrence Score as an Adjuvant-Treatment Decision Tool in Early Breast Cancer Patients. European Journal of Cancer. 47. S379–S379. 2 indexed citations
10.
Pappas, Athanasios, et al.. (2010). The value of proliferation indexes in breast cancer.. PubMed. 31(2). 181–4. 10 indexed citations
11.
Pappas, Athanasios, et al.. (2010). Analysis of clinical and molecular associations of triple negative breast cancers in node-negative patients.. PubMed. 31(3). 304–7. 1 indexed citations
12.
Markopoulos, Christos, Urania Dafni, Grigorios Xepapadakis, et al.. (2010). Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Research. 12(2). R24–R24. 63 indexed citations
13.
Patsouris, E, et al.. (2010). 194 DNA ploidy in relationship with EZH2 expression as markers of breast carcinomas. European Journal of Cancer Supplements. 8(3). 114–114. 1 indexed citations
14.
Markopoulos, Christos, Urania Dafni, Dimitrios Koukouras, et al.. (2009). Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Research. 11(3). R35–R35. 31 indexed citations
15.
Markopoulos, Christos, Vasileios Venizelos, Grigorios Xepapadakis, et al.. (2009). Management of bone loss in breast cancer patients: 24-month results from the ARBI trial of anastrozole with risedronate. Journal of Clinical Oncology. 27(15_suppl). 552–552. 2 indexed citations
16.
Markopoulos, Christos, et al.. (2008). Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Annals of Oncology. 20(1). 49–55. 33 indexed citations
17.
Markopoulos, Christos, et al.. (2006). Duration of Tamoxifen Effect on Lipidemic Profile of Postmenopausal Breast Cancer Patients following Deprivation of Treatment. Oncology. 70(4). 301–305. 8 indexed citations
18.
19.
Markopoulos, Christos, et al.. (2005). The Effect of Exemestane on the Lipidemic Profile of Postmenopausal Early Breast Cancer Patients: Preliminary Results of the TEAM Greek Sub-study. Breast Cancer Research and Treatment. 93(1). 61–66. 54 indexed citations
20.
Stathopoulos, G., et al.. (1997). Long term breast cancer treatment with tamoxifen and second primary tumors. European Journal of Cancer. 33. S150–S151. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Judy-Anne W. Chapman Breakdown of academic impact, for papers by Andrea De Censi Breakdown of academic impact, for papers by S. Ashley Breakdown of academic impact, for papers by Messan G. Amewou-Atisso Breakdown of academic impact, for papers by Henrik Csaba Horváth Breakdown of academic impact, for papers by S.E. Bulun Breakdown of academic impact, for papers by T. Vandorpe Breakdown of academic impact, for papers by Rosalind Wilson Breakdown of academic impact, for papers by C. A. Haiman Breakdown of academic impact, for papers by Angeline A. Giangreco
Rankless by CCL
2026